<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02442375</url>
  </required_header>
  <id_info>
    <org_study_id>UPGRADE-RT v3.4 dd20170724</org_study_id>
    <nct_id>NCT02442375</nct_id>
  </id_info>
  <brief_title>Uniform FDG‐PET Guided Gradient Dose Prescription to Reduce Late Radiation Toxicity</brief_title>
  <acronym>UPGRADE-RT</acronym>
  <official_title>Uniform FDG‐PET Guided GRAdient Dose prEscription to Reduce Late Radiation Toxicity (UPGRADE‐RT): a Randomised Controlled Trial With Dose Reduction to the Elective Neck in Head and Neck Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastro Clinic, The Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radiotherapiegroep</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radiotherapeutisch Instituut Friesland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the UPGRADE-RT trial is to investigate whether de-escalation of elective
      radiation dose and introduction of an intermediate dose-level in the treatment of head and
      neck cancer will results in less radiation sequelae and improved quality of life after
      treatment whilst the recurrence rate in electively irradiated lymph nodes should not be
      compromised.

      A summary of the study protocol can be found here: http://rdcu.be/qgMv
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity: normalcy of diet (score of the performance status scale for head and neck cancer patients)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: recurrence in electively irradiated lymph nodes</measure>
    <time_frame>24 months</time_frame>
    <description>A Kaplan-Meier estimate will be calculated</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Acute toxicity (common toxicity criteria v2.0)</measure>
    <time_frame>up to 3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Late toxicity: swallowing function (water swallowing test)</measure>
    <time_frame>3, 12 and 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Late toxicity: salivary gland function (stimulated flow rates)</measure>
    <time_frame>3, 12 and 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Late toxicity: thyroid gland function (thyroid stimulating hormone blood test)</measure>
    <time_frame>3, 12 and 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life (EORTC QLQ‐C30 and QLQ‐H&amp;N35 questionnaires)</measure>
    <time_frame>3, 6, 12 and 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Xerostomia related quality of life (GRIX questionnaire)</measure>
    <time_frame>3, 6, 12 and 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Dysphagia related quality of life (SWAL-QOL questionnaire)</measure>
    <time_frame>3, 6, 12 and 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Loco-regional control</measure>
    <time_frame>24 months</time_frame>
    <description>A Kaplan-Meier estimate will be calculated</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months</time_frame>
    <description>A Kaplan-Meier estimate will be calculated</description>
  </other_outcome>
  <other_outcome>
    <measure>Disease specific survival</measure>
    <time_frame>24 months</time_frame>
    <description>A Kaplan-Meier estimate will be calculated</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Head and Neck Neoplasms</condition>
  <condition>Carcinoma, Squamous Cell</condition>
  <arm_group>
    <arm_group_label>standard dose prescription</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FDG-PET-scan in treatment mask for radiotherapy planning
Accelerated radiotherapy IMRT/VMAT with SIB (34 fraction in 5.5 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FDG‐PET guided gradient dose prescription</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FDG-PET-scan in treatment mask for radiotherapy planning
Accelerated radiotherapy IMRT/VMAT with SIB (34 fraction in 5.5 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>standard dose prescription</intervention_name>
    <description>standard elective dose
no intermediate dose-level
visual interpretation of FDG-PET-scan</description>
    <arm_group_label>standard dose prescription</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>FDG‐PET guided gradient dose prescription</intervention_name>
    <description>de-escalation of elective dose
intermediate dose-level
standardized methods to evaluate FDG-PET-scan</description>
    <arm_group_label>FDG‐PET guided gradient dose prescription</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Newly diagnosed tumours classified as stage T2‐4 N0‐2 located in the larynx,
             oropharynx or hypopharynx (unknown primary and oral cavity are not eligible)

          2. Histopathological diagnosis of invasive squamous cell carcinoma in the primary tumour

          3. Decision for curative intent external beam radiotherapy with elective treatment of the
             neck made by a multidisciplinary head‐and‐neck oncology team. The patient must be
             expected to complete the treatment.

          4. Radiotherapy planned to start within 6 weeks from baseline imaging of tumour
             assessment

          5. No distant metastasis (M0)

          6. WHO performance status 0‐2

          7. ≥ 18 years of age

          8. Written informed consent

        Exclusion Criteria:

          1. Concomitant chemotherapy or EGFR inhibitors for this tumour.

          2. Primary tumour of the oral cavity or unknown primary tumour

          3. Prior or current anticancer treatment to the head and neck area (e.g. radical
             attempted or tumour reductive surgery, neo‐adjuvant or concomitant chemotherapy, EGFR
             inhibitors or radiotherapy), except for endoscopic glottic laser micro surgery.

          4. Current participation in any other interventional clinical study.

          5. Uncontrolled diabetes mellitus.

          6. Known or suspected HIV infection.

          7. History of previous malignancy within the last 3 years, with the exception of
             surgically cured carcinoma in situ of the cervix, in situ breast cancer, incidental
             finding of stage T1a or T1b prostate cancer, and basal/squamous cell carcinoma of the
             skin.

          8. Any condition (somatic, psychological, familial, sociological or geographical)
             rendering the patient unable to understand or complete questionnaires.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Dr. J.H.A.M. Kaanders</last_name>
    <role>Study Chair</role>
    <affiliation>Radboud University Nijmegen Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Drs. S. van den Bosch</last_name>
    <phone>+31 (0) 24 361 45 15</phone>
    <email>sven.vandenbosch@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dr. T. Dijkema</last_name>
    <phone>+31 (0) 24 361 45 15</phone>
    <email>tim.dijkema@radboudumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VU University Medical Center Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Drs. M.R. Vergeer</last_name>
      <phone>+31 (0) 20 44 415 71</phone>
      <email>mr.vergeer@vumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radiotherapiegroep, Arnhem</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. B. Kreike</last_name>
      <phone>+31 (0) 26 37 12 412</phone>
      <email>b.kreike@arnhemrti.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radiotherapeutisch Instituut Friesland</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. O.B. Wijers</last_name>
      <phone>+31 (0) 58 28 66 667</phone>
      <email>o.b.wijers@skf-rif.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MAASTRO clinic, Maastricht</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. F.J.P. Hoebers</last_name>
      <phone>+31 (0) 88 44 55 666</phone>
      <email>frank.hoebers@maastro.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Dr. J.H.A.M. Kaanders</last_name>
      <phone>+31 (0) 24 361 45 15</phone>
      <email>j.kaanders@radboudumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Drs. S. van den Bosch</last_name>
      <phone>+31 (0) 24 361 45 15</phone>
      <email>sven.vandenbosch@radboudumc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Dr. C.H.J. Doornaert</last_name>
      <phone>+31 (0) 88 75 588 00</phone>
      <email>P.A.H.Doornaert@umcutrecht.nl</email>
    </contact>
    <contact_backup>
      <last_name>Dr. P.A.H. Terhaard</last_name>
      <phone>+31 (0) 88 75 588 00</phone>
      <email>c.h.j.terhaard@umcutrecht.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://rdcu.be/qgMv</url>
    <description>Study protcol</description>
  </link>
  <reference>
    <citation>van den Bosch S, Dijkema T, Kunze-Busch MC, Terhaard CH, Raaijmakers CP, Doornaert PA, Hoebers FJ, Vergeer MR, Kreike B, Wijers OB, Oyen WJ, Kaanders JH. Uniform FDG-PET guided GRAdient Dose prEscription to reduce late Radiation Toxicity (UPGRADE-RT): study protocol for a randomized clinical trial with dose reduction to the elective neck in head and neck squamous cell carcinoma. BMC Cancer. 2017 Mar 21;17(1):208. doi: 10.1186/s12885-017-3195-7.</citation>
    <PMID>28327089</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2015</study_first_submitted>
  <study_first_submitted_qc>May 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2015</study_first_posted>
  <last_update_submitted>September 18, 2017</last_update_submitted>
  <last_update_submitted_qc>September 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>head and neck cancer</keyword>
  <keyword>accelerated radiotherapy</keyword>
  <keyword>dose reduction</keyword>
  <keyword>dose de-escalation</keyword>
  <keyword>elective lymph nodes</keyword>
  <keyword>FDG-PET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

